Please assess the completion status of the following clinical trial:

Trial Title: An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18- 75 years~2. Colonic lesion that should be removed surgically:~3. 2.a. CRC that is potentially resectable and not requiring neoadjuvant treatment.~4. 2.b. Endoscopically non-resectable adenoma.~5. 2.c. Familial Adenomatous Polyposis (FAP) patient that requires colectomy or proctocolectomy.~6. Need for perioperative colonoscopy as a part of standard of care evaluation:~7. 6.a. CRC or adenoma for which the colorectal surgeon requires a preoperative colonoscopy or sigmoidoscopy for any reason, including but not limited to:~8. 6.a.a. No outside colonoscopy~9. 6.a.b. No outside pathology~10. 6.a.c. Partially obstructing tumor or~11. 6.a.d. Otherwise unsatisfactory outside colonoscopy~12. 6.a.e. Rectal cancer requiring EUS~13. 6.a.f. Second opinion on adenoma regarded as endoscopically non-resectable on outside colonoscopy; or~14. 6.b. Patient found on initial MDACC colonoscopy to have CRC or endoscopically non-resectable adenoma, most commonly patients undergoing average or high risk (familial, history of adenoma) screening colonoscopy.~15. Ability to give informed consent.~16. Diabetic patients are eligible but they may be excluded if they are taking Metformin, insulin or sulfonylureas.~Exclusion Criteria:~1. Patients with renal insufficiency defined as serum creatinine \>= 1.4 mg/dl for females and \>= 1.5 mg/dl for males~2. Pregnant or nursing women~3. A malignancy currently under active therapy~4. Unstable angina~5. Uncontrolled ischemic cardiac disease or symptomatic congestive heart failure (e.g. Class III or IV New York Heart Association's Functional Classification)~6. Current usage of Metformin~7. Current usage of insulin, sulfonylureas~8. History of lactic acidosis~9. Chronic liver disease or cirrhosis~10. Inability to give informed consent~11. Other investigational drugs within the past one year or concurrently~12. Known hypersensitivity or intolerance to Metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Metformin + Colon Surgery (Type: EXPERIMENTAL): Patients randomized to Metformin-ER 500 mg once daily for one week and then escalation to 1000 mg/day for the duration of the trial. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
- Colon Surgery Alone (Type: NO_INTERVENTION): Patients will not receive any study drug from the time of colonoscopy until surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).